Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab neoadjuvant and adjuvant therapy in resectable LA HNSCC
jRCT2080224953Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial in head and neck squamous cell carcinoma (HNSCC), oropharyngeal squamous cell carcinoma (OPSCC), laryngeal squamous cell carcinoma (LSCC) and 2 more comparing Pembrolizumab neoadjuvant + pembrolizumab SOC adjuvant with Standard-of-care adjuvant radiotherapy ± cisplatin (2 arms). Started Nov 2019; status: completed.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)oropharyngeal squamous cell carcinoma (OPSCC)laryngeal squamous cell carcinoma (LSCC)squamous cell carcinoma of the hypopharynxOral Mucosal Carcinoma
Beyond the preview
Go deeper on jRCT2080224953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224953.